Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Toni Choueiri, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Lank Center for Genitourinary Oncology
  • Director, Kidney Cancer Center
  • Senior Physician
  • Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Bladder cancer
  • Genitourinary tumors
  • Renal cell carcinoma (kidney)

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-632-5456
  • Fax617-632-2165

Bio

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI)/Brigham and Women’s Hospital and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the GU Steering Committee (GUSC) Task Force of the National Cancer Institute (NCI), and is past Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association and past president of the Medical Staff at DFCI.Dr. Choueiri is interested in developing novel therapies and biomarkers in GU malignancies, including kidney cancer. His research also focuses on epidemiology, diagnosis, biomarkers, and clinical trials of GU cancers. He has been funded by the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), the Harvard Kidney Cancer SPORE, and Industry partners. His work has been published in journals such as the New England Journal of Medicine, Nature, Science, Cancer Cell, Journal of American Medical Association, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, and many others. He has over 500 PubMed-listed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.

Board Certification:

  • Internal Medicine, 2004
  • Medical Oncology, 2007

Fellowship:

  • Cleveland Clinic Foundation, Hematology/Medical Oncology

Residency:

  • Cleveland Clinic Foundation, Internal Medicine

Medical School:

  • Saint Joseph University Faculte of Medicine

Research

Novel therapies in genitourinary cancers with a focus on kidney cancers

Dr. Choueiri is interested in the clinical and molecular predictors of outcome to therapies in renal cancers.

Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. In: Curr Opin Investig Drugs. Thompson Scientific; 2008. p. 658-71.

2008

Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009; 10: 967-74.

2009

Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Cane Netw. 2009; 7: 659-65.

2009

Lotan, Y, Choueiri, TK. Clinical presentations, diagnosis, and staging of bladder cancer. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2010.

2010

Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, and Escudier B. Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. J Clin Oncol. 2008;26(1):127-131.

Escudier B, Choueiri TK, Oudard S, Szczylik C, Ngrier S, Ravaud A, Chevreau C, Venner P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM. Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. J Urol. 2007: pp. 1901-1905.

Choueiri TK,Tamaskar I, Sercia L, Rini B, Bukowski R, Zhou M. Differential expression of caveolin-1 in renal neoplasms. Cancer. 2007;110(4):776-82.

Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110(3):543-50

Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007;18(2):249-55.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006;107(11):2609-16.

Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed J, Faiman B, Hussein M. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica. 2006;9 (10):1410-3.

Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30(9):1097-104.

Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006;17(5):860-5.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top